British consumer healthcare company Haleon announced Wednesday that its revenue growth decelerated during the final quarter of last year, citing a late-arriving flu season that dampened sales of cold and respiratory medications.
The company, known for manufacturing Sensodyne toothpaste, saw its respiratory health product sales suffer due to an unusually mild cold and flu season, especially across North America and Central and Eastern Europe. This challenge was made worse by reduced consumer spending in the United States and increased market competition that pushed customers toward more affordable options, particularly affecting the company’s underperforming Smokers’ Health product line.
During the October-through-December period, Haleon’s organic revenue increased by 2.1%, marking a decline from the previous quarter’s 3.4% growth rate.
Looking ahead to 2026, the company projects organic revenue growth will fall between 3% and 5%, which falls short of the 4.4% growth rate that market analysts had anticipated, based on a survey conducted by the company.
